Prognostic value of ALDH2 polymorphism for patients with oropharyngeal cancer in a Japanese population

PLoS One. 2017 Dec 5;12(12):e0187992. doi: 10.1371/journal.pone.0187992. eCollection 2017.

Abstract

Background: Half of Japanese possess a polymorphism of aldehyde dehydrogenase 2(ALDH2), while few white individuals possess this mutation. The purpose of this study was to investigate the possibility of ALDH2 polymorphism as a prognostic factor for oropharyngeal cancer (OPC) among Japanese population.

Methods: We analyzed 82 Japanese patients with OPC treated between 2006 and 2011. The median observation period was 50 months. P16-staining and ALDH2 polymorphisms were investigated. To examine the frequencies of second primary pharyngeal and esophageal cancers (SPPEC),37 Japanese patients with OPC treated at Tokyo University Hospital were included for statistical analysis.

Results: Statistically significant differences were noted in OS among sex, age, N classification, and p16 (p = 0.045, 0.024, 0.020, 0.007, respectively). In addition, OS and DSS rates of the patients with heterozygous ALDH2 tended to be worse than those of the patients with homozygous ALDH2 (p = 0.21, 0.086, respectively). Of note, OS and DSS of the patients with p16-negative OPC and heterozygous ALDH2 was significant poorer than those of the patients with p16-positive OPC (p = 0.002, 0.006, respectively), while there was no significant difference in OS and DSS between patients with p16-positive OPC and patients with p16-negative OPC and homozygous ALDH2.

Conclusions: ALDH2 polymorphism might be a promising prognostic factor for Japanese patients with p16-negative OPC.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Aldehyde Dehydrogenase, Mitochondrial / genetics*
  • Female
  • Humans
  • Japan
  • Male
  • Middle Aged
  • Oropharyngeal Neoplasms / enzymology
  • Oropharyngeal Neoplasms / pathology*
  • Prognosis
  • Survival Rate

Substances

  • ALDH2 protein, human
  • Aldehyde Dehydrogenase, Mitochondrial

Grants and funding

This work is partly supported by Grant-in-Aid for Scientific Research (26861379, H. S. & 16H0548, 16H05481 K.N) and Japan Agency for Medical Research and Development (16ck0106223h001, K.N.).